2
项与 ChAd-triCoV/Mac(McMaster University) 相关的临床试验A Phase 2 Trial to Evaluate Safety and Immunogenicity of a Next-generation COVID-19 Vaccine Delivered by Inhaled Aerosol to Humans
The goal of this clinical trial is to study the safety of a new inhaled vaccine to prevent COVID infection and learn about the immune responses that are made in the lungs and the blood after vaccination. Participants will be randomized (like the toss of a coin) to receive the experimental vaccine or a placebo (a look-alike solution that contains no vaccine).
To be in the study participants will have to have already had three doses of a messenger ribonucleic acid (mRNA) COVID vaccine and be generally healthy. Participants are given a single dose of the vaccine by breathing in a fine mist that goes directly into the lungs.
During follow-up participants will:
* visit the clinic for checkups and blood tests at 2, 4 and 8 weeks after vaccination
* report their symptoms for 24 weeks after getting the vaccine.
In some participants, the researchers will collect cells from the lung 4 weeks after vaccination (a test known as a bronchoscopy).
/ Active, not recruiting临床1期IIT Phase 1, Open Label Study to Evaluate the Safety and Immunogenicity of ChAd68 and AdHu5 Vector-based Trivalent COVID-19 Vaccines Delivered Via Inhaled Aerosol
This is a phase 1 study in healthy volunteers who have received at least three doses of an mRNA COVID-19 vaccine, to evaluate the safety and immune responses that develop in the blood and lungs following the administration by aerosol of either Ad5-triCoV/Mac or ChAd-triCoV/Mac, new experimental adenovirus-based vaccines expressing SARS-CoV-2 spike, nucleocapsid and RNA polymerase proteins.
100 项与 ChAd-triCoV/Mac(McMaster University) 相关的临床结果
100 项与 ChAd-triCoV/Mac(McMaster University) 相关的转化医学
100 项与 ChAd-triCoV/Mac(McMaster University) 相关的专利(医药)
100 项与 ChAd-triCoV/Mac(McMaster University) 相关的药物交易